RSS Feeds
Resolution of Severe Digital Ulceration during a Course of Bosentan Therapy
- Michael J. Snyder, MD;
- Mary R. Jacobs, MD;
- Rafael G. Grau, MD;
- David S. Wilkes, MD; and
- Kenneth S. Knox, MD
- From Indiana University School of Medicine, Indianapolis, IN 46202.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Bosentan, the dual endothelin-receptor antagonist, has proven efficacy for treatment of secondary pulmonary arterial hypertension in patients with systemic sclerosis (1). Preliminary observations suggest a role for endothelin antagonist therapy in patients with systemic sclerosis who experience the Raynaud phenomenon and associated digital ulceration (2).
Objective: …
This 100-word excerpt has been provided in the absence of an abstract.
